{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:43:54Z","timestamp":1790837034198,"version":"4.1.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0337_abs_001_w2aab3b7c51b1b6b1aab1c15b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Glycated hemoglobin (HbA1c) has proven to be indicative in the development of microvascular complications. In this study, the contribution of HbA1c variability to microvascular complications was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0337_abs_002_w2aab3b7c51b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-one cases with type 1 diabetes mellitus (T1DM) who developed microvascular complications and 39 cases without complications, that were similar in terms of gender, age of diagnosis, insulin treatment, insulin doses (U\/kg), and mean HbA1c levels were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0337_abs_003_w2aab3b7c51b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean age of T1DM diagnosis was 5.87\u00a0\u00b1\u00a03.93 years in the complication group and 4.63\u00a0\u00b1\u00a03.33 years in the control group. Nephropathy was detected in 17 cases, neuropathy in 8 cases, and retinopathy in 1 case. Nephropathy occurred at a mean age of 11.52\u00a0\u00b1\u00a04.12 years and neuropathy at 14.13\u00a0\u00b1\u00a05.68 years. The mean HbA1c during follow-up was similar in the group with complications and the control group (8.60\u00a0\u00b1\u00a00.63 vs. 8.84\u00a0\u00b1\u00a01.32). Adjusted HbA1c-standard deviation (SD) and HbA1c-variation coefficient (CV) values were 1.30\u00a0\u00b1\u00a00.65 and 14.36\u00a0\u00b1\u00a06.23 in the group with complications (p=0.014), and 0.91\u00a0\u00b1\u00a00.37 and 10.59\u00a0\u00b1\u00a04.01 in the control group (p=0.013). In the Receiver Operating Characteristic (ROC)-analysis for microvascular complications, the limit value HbA1c-CV was 11.99 (sensitivity: 61.9%, specificity: 71.9%). This value for HbA1c-SD was 0.9699 (sensitivity: 71.43%, specificity: 66.67%)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0337_abs_004_w2aab3b7c51b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study has shown that long-term fluctuations in HbA1c are associated with the development of microvascular complications in type 1 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0337","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T10:47:05Z","timestamp":1608634025000},"page":"1533-1537","source":"Crossref","is-referenced-by-count":6,"title":["Glycated hemoglobin variability and microvascular complications in patients with type\u00a01 diabetes mellitus"],"prefix":"10.1515","volume":"33","author":[{"given":"Eren","family":"Er","sequence":"first","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Ata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferda","family":"Evin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin Atik","family":"Alt\u0131nok","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnay","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samim","family":"\u00d6zen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e\u00fckran","family":"Darcan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"G\u00f6k\u015fen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Faculty of Medicine , Division of Pediatric Endocrinology, School of Medicine, Ege University , \u0130zmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"2023040101094810709_j_jpem-2020-0337_ref_001_w2aab3b7c51b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Nathan, DM, for the DCCT\/EDIC Research Group. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 Years: overview [Internet]. Diabetes Care 2014;37:9\u201316. Available from: http:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc13-2112 [cited 2020 Mar 30].","DOI":"10.2337\/dc13-2112"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_002_w2aab3b7c51b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"On behalf of the FinnDiane Study Group, Harjutsalo, V, Maric-Bilkan, C, Forsblom, C, Groop, P-H. Age at menarche and the risk of diabetic microvascular complications in patients with type 1 diabetes [Internet]. Diabetologia 2016;59:472\u201380. Available from: http:\/\/link.springer.com\/10.1007\/s00125-015-3816-0 [cited 2019 Oct 28].","DOI":"10.1007\/s00125-015-3816-0"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_003_w2aab3b7c51b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Andreasson, R, Ekelund, C, Landin-Olsson, M, Nilsson, C. HbA1c levels in children with type 1 diabetes and correlation to diabetic retinopathy [Internet]. J Pediatr Endocrinol Metab 2018;31:369\u201374. Available from: https:\/\/www.degruyter.com\/doi\/10.1515\/jpem-2017-0417 [cited 2020 Aug 14].","DOI":"10.1515\/jpem-2017-0417"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_004_w2aab3b7c51b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes\u00a0control and complications trial. Diabetes 1995;44:968\u201383. https:\/\/doi.org\/10.2337\/diab.44.8.968.","DOI":"10.2337\/diab.44.8.968"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_005_w2aab3b7c51b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Couper, JJ, Haller, MJ, Greenbaum, CJ, Ziegler, A-G, Wherrett, DK, Knip, M, et al.. ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents [Internet]. Pediatr Diabetes 2018;19:20\u20137. Available from: http:\/\/doi.wiley.com\/10.1111\/pedi.12734 [cited 2019 Oct 28].","DOI":"10.1111\/pedi.12734"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_006_w2aab3b7c51b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Neyzi, O, Bundak, R, G\u00f6k\u00e7ay, G, G\u00fcn\u00f6z, H, Furman, A, Darendeliler, F, et al.. Reference values for weight, height, head circumference, and body mass index in Turkish children [Internet]. Jcrpe 2015;7:280\u201393. Available from: http:\/\/cms.galenos.com.tr\/Uploads\/Article_1419\/JCRPE-7-280.pdf [cited 2019 Oct 28].","DOI":"10.4274\/jcrpe.2183"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_007_w2aab3b7c51b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Demir, K, \u00d6zen, S, Konak\u00e7\u0131, E, Ayd\u0131n, M, Darendeliler, F. A comprehensive online calculator for pediatric endocrinologists: \u00c7EDD \u00c7\u00f6z\u00fcm\/TPEDS metrics. J Clini 2017;9:182\u20134. https:\/\/doi.org\/10.4274%2Fjcrpe.4526.","DOI":"10.4274\/jcrpe.4526"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_008_w2aab3b7c51b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Donaghue, KC, Marcovecchio, ML, Wadwa, RP, Chew, EY, Wong, TY, Calliari, LE, et al.. ISPAD clinical practice consensus guidelines 2018: microvascular and macrovascular complications in children and adolescents [Internet]. Pediatr Diabetes 2018;19:262\u201374. Available from: http:\/\/doi.wiley.com\/10.1111\/pedi.12742 [cited 2020 Apr 30].","DOI":"10.1111\/pedi.12742"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_009_w2aab3b7c51b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Kilpatrick, ES, Rigby, AS, Atkin, SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial [Internet]. Diabetes Care 2008;31:2198\u2013202. Available from: http:\/\/care.diabetesjournals.org\/cgi\/doi\/10.2337\/dc08-0864 [cited 2020 Apr 17].","DOI":"10.2337\/dc08-0864"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_010_w2aab3b7c51b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"De Nigris, V, Pujadas, G, La Sala, L, Testa, R, Genovese, S, Ceriello, A. Short-term high glucose exposure impairs insulin signaling in endothelial cells [Internet]. Cardiovasc Diabetol 2015;14:114. Available from: http:\/\/www.cardiab.com\/content\/14\/1\/114 [cited 2020 Apr 17].","DOI":"10.1186\/s12933-015-0278-0"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_011_w2aab3b7c51b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Ceriello, A, Esposito, K, Piconi, L, Ihnat, MA, Thorpe, JE, Testa, R, et al.. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients [Internet]. Diabetes 2008;57:1349\u201354. Available from: http:\/\/diabetes.diabetesjournals.org\/cgi\/doi\/10.2337\/db08-0063 [cited 2020 Apr 18].","DOI":"10.2337\/db08-0063"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_012_w2aab3b7c51b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"\u00d3lafsd\u00f3ttir, AF, Polonsky, W, Bolinder, J, Hirsch, IB, Dahlqvist, S, Wedel, H, et al.. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3) [Internet]. Diabetes Technol Therapeut 2018;20:274\u201384. Available from: http:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2017.0363 [cited 2020 Mar 31].","DOI":"10.1089\/dia.2017.0363"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_013_w2aab3b7c51b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Kilpatrick, ES. The rise and fall of HbA1c as a risk marker for diabetes complications [Internet]. Diabetologia 2012;55:2089\u201391. Available from: http:\/\/link.springer.com\/10.1007\/s00125-012-2610-5 [cited 2020 Apr 18].","DOI":"10.1007\/s00125-012-2610-5"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_014_w2aab3b7c51b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Gorst, C, Kwok, CS, Aslam, S, Buchan, I, Kontopantelis, E, Myint, PK, et al.. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis [Internet]. Diabetes Care 2015;38:2354\u201369. Available from: http:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc15-1188 [cited 2020 Apr 18].","DOI":"10.2337\/dc15-1188"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_015_w2aab3b7c51b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Hsu, CC, Chang, HY, Huang, MC, Hwang, SJ, Yang, YC, Lee, YS, et al.. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study [Internet]. Diabetologia 2012;55:3163\u201372. Available from: http:\/\/link.springer.com\/10.1007\/s00125-012-2700-4 [cited 2020 Apr 17].","DOI":"10.1007\/s00125-012-2700-4"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_016_w2aab3b7c51b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Cheng, D, Fei, Y, Liu, Y, Li, J, Xue, Q, Wang, X, et al.. HbA1C variability and the risk of renal status progression in diabetes mellitus: a meta-analysis. In: Jandeleit-Dahm, K, editor. PLoS ONE [Internet]; 2014, vol 9. Available from: http:\/\/dx.plos.org\/10.1371\/journal.pone.0115509 e115509. [cited 2020 Apr 18].","DOI":"10.1371\/journal.pone.0115509"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_017_w2aab3b7c51b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Matsutani, D, Sakamoto, M, Minato, S, Kayama, Y, Takeda, N, Horiuchi, R, et al.. Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes [Internet]. Cardiovasc Diabetol 2018;17:100. Available from: https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0743-7 [cited 2020 Apr 17].","DOI":"10.1186\/s12933-018-0743-7"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_018_w2aab3b7c51b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Walker, GS, Cunningham, SG, Sainsbury, CAR, Jones, GC. HbA 1c variability is associated with increased mortality and earlier hospital admission in people with Type 1 diabetes [Internet]. Diabet Med 2017;34:1541\u20135. Available from: http:\/\/doi.wiley.com\/10.1111\/dme.13455 [cited 2020 Apr 17].","DOI":"10.1111\/dme.13455"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_019_w2aab3b7c51b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Hermann, JM, Hammes, H-P, Rami-Merhar, B, Rosenbauer, J, Sch\u00fctt, M, Siegel, E, et al.. HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German\/Austrian multicenter analysis on 35,891 patients. In: von Herrath, MG, editor. PLoS ONE [Internet]; 2014, vol 9. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0091137 [cited 2020 Apr 18].e91137.","DOI":"10.1371\/journal.pone.0091137"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_020_w2aab3b7c51b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Alleyn, CR, Volkening, LK, Wolfson, J, Rodriguez-Ventura, A, Wood, JR, Laffel, LMB. Occurrence of microalbuminuria in young people with\u00a0Type 1 diabetes: importance of age and diabetes duration: microalbuminuria in young people with Type 1 diabetes [Internet]. Diabet Med 2010;27:532\u20137. Available from: http:\/\/doi.wiley.com\/10.1111\/j.1464-5491.2010.02983.x [cited 2020 Apr 18].","DOI":"10.1111\/j.1464-5491.2010.02983.x"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_021_w2aab3b7c51b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Nazim, J, Fendler, W, Starzyk, J. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes. Endokrynologia Polska 2014;65:83\u201389. https:\/\/doi.org\/10.5603\/EP.2014.0012.","DOI":"10.5603\/EP.2014.0012"},{"key":"2023040101094810709_j_jpem-2020-0337_ref_022_w2aab3b7c51b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Su, J, Zhao, L, Zhang, X, Cai, H, Huang, H, Xu, F, et al.. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients [Internet]. Cardiovasc Diabetol 2018;17:47. Available from: https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0693-0 [cited 2020 Apr 17].","DOI":"10.1186\/s12933-018-0693-0"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/33\/12\/article-p1533.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0337\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0337\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T18:34:58Z","timestamp":1680374098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0337\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,9]]},"published-print":{"date-parts":[[2020,12,16]]}},"alternative-id":["10.1515\/jpem-2020-0337"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0337","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}